


Irene Cox

Sample Work: conceptual 1

A stage with a brick wall and a spotlight on a wooden floor. A red curtain is visible on the left side of the stage.

Set the stage for HRRm testing

HRRm testing is a major shift in the management of prostate cancer and a step toward precision medicine. Does your practice have a protocol for gene testing in patients with metastatic prostate cancer?

Genetic testing for mutations that identify the risk of prostate cancer

In metastatic prostate cancer,

ENLIGHTEN TREATMENT PLANNING...



...WITH HRR MUTATION TESTING

HRR mutation status provides valuable insights that can inform prognosis, hereditary risk, treatment decisions, and eligibility for clinical trials. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend germline and tumor testing for HRR gene mutations in all men with metastatic prostate cancer.


BTK inhibitor—a treatment that's straight with you.

Now you can put aside the complexity of infusions and monitoring for patients with CLL. Choose a treatment option that's effective, safe—and easy to take. A BTK inhibitor: experience the difference.




Treating chronic lymphocytic leukemia

IN CLL TREATMENT,
**DISEASE DISRUPTION REQUIRES
CONTINUOUS CARE**



BTK inhibitors offer an effective approach to CLL management—
continuous treatment for long-term disease control.

AstraZeneca 



Promoting the MKG company called MEI

**With MEI, your brand's assets will be
universally admired.**

**With our analytics, medical expertise, and strategic
creative vision, you'll be as mesmerized by
our process as customers are by your brand.**